nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—osteoarthritis—Methylprednisolone—multiple sclerosis	0.24	0.5	CpDpCtD
Sulindac—osteoarthritis—Prednisone—multiple sclerosis	0.24	0.5	CpDpCtD
Sulindac—ALB—multiple sclerosis	0.139	1	CbGaD
Sulindac—PTGS2—Triamcinolone—multiple sclerosis	0.0389	0.261	CbGbCtD
Sulindac—PTGS2—Betamethasone—multiple sclerosis	0.0334	0.224	CbGbCtD
Sulindac—ALB—Prednisone—multiple sclerosis	0.0196	0.132	CbGbCtD
Sulindac—PTGS2—Dexamethasone—multiple sclerosis	0.0194	0.13	CbGbCtD
Sulindac—CYP1A1—Dexamethasone—multiple sclerosis	0.0164	0.11	CbGbCtD
Sulindac—AKR1B1—sciatic nerve—multiple sclerosis	0.014	0.306	CbGeAlD
Sulindac—SLC22A6—Methotrexate—multiple sclerosis	0.0116	0.0775	CbGbCtD
Sulindac—ALB—Methotrexate—multiple sclerosis	0.00985	0.066	CbGbCtD
Sulindac—AKR1B1—peripheral nervous system—multiple sclerosis	0.00536	0.117	CbGeAlD
Sulindac—AKR1B1—retina—multiple sclerosis	0.00173	0.0379	CbGeAlD
Sulindac—PTGDR2—cerebellum—multiple sclerosis	0.00166	0.0364	CbGeAlD
Sulindac—PTGS2—leg—multiple sclerosis	0.00145	0.0317	CbGeAlD
Sulindac—PTGDR2—brain—multiple sclerosis	0.00135	0.0296	CbGeAlD
Sulindac—MAPK3—retina—multiple sclerosis	0.00125	0.0275	CbGeAlD
Sulindac—AKR1B1—medulla oblongata—multiple sclerosis	0.00125	0.0274	CbGeAlD
Sulindac—AKR1B1—midbrain—multiple sclerosis	0.00114	0.025	CbGeAlD
Sulindac—AKR1B1—spinal cord—multiple sclerosis	0.00112	0.0244	CbGeAlD
Sulindac—AKR1B1—nervous system—multiple sclerosis	0.00094	0.0206	CbGeAlD
Sulindac—MAPK3—medulla oblongata—multiple sclerosis	0.000907	0.0199	CbGeAlD
Sulindac—AKR1B1—central nervous system—multiple sclerosis	0.000905	0.0198	CbGeAlD
Sulindac—PPARD—midbrain—multiple sclerosis	0.000899	0.0197	CbGeAlD
Sulindac—AKR1B1—cerebellum—multiple sclerosis	0.000884	0.0194	CbGeAlD
Sulindac—MAPK3—midbrain—multiple sclerosis	0.000829	0.0182	CbGeAlD
Sulindac—MAPK3—spinal cord—multiple sclerosis	0.000808	0.0177	CbGeAlD
Sulindac—PPARD—nervous system—multiple sclerosis	0.000739	0.0162	CbGeAlD
Sulindac—AKR1B1—brain—multiple sclerosis	0.000718	0.0157	CbGeAlD
Sulindac—PPARD—central nervous system—multiple sclerosis	0.000711	0.0156	CbGeAlD
Sulindac—PPARD—cerebellum—multiple sclerosis	0.000695	0.0152	CbGeAlD
Sulindac—MAPK3—nervous system—multiple sclerosis	0.000681	0.0149	CbGeAlD
Sulindac—MAPK3—central nervous system—multiple sclerosis	0.000656	0.0144	CbGeAlD
Sulindac—MAPK3—cerebellum—multiple sclerosis	0.000641	0.014	CbGeAlD
Sulindac—PPARD—brain—multiple sclerosis	0.000565	0.0124	CbGeAlD
Sulindac—MAPK3—brain—multiple sclerosis	0.000521	0.0114	CbGeAlD
Sulindac—SLC22A6—brain—multiple sclerosis	0.000398	0.00872	CbGeAlD
Sulindac—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000335	0.159	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000329	0.156	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000329	0.156	CbGdCrCtD
Sulindac—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000322	0.153	CbGdCrCtD
Sulindac—ALB—brain—multiple sclerosis	0.000248	0.00544	CbGeAlD
Sulindac—PTGS2—medulla oblongata—multiple sclerosis	0.000235	0.00516	CbGeAlD
Sulindac—PTGS1—spinal cord—multiple sclerosis	0.00022	0.00481	CbGeAlD
Sulindac—PTGS2—midbrain—multiple sclerosis	0.000215	0.00471	CbGeAlD
Sulindac—CYP1A1—nervous system—multiple sclerosis	0.000211	0.00462	CbGeAlD
Sulindac—PTGS2—spinal cord—multiple sclerosis	0.00021	0.0046	CbGeAlD
Sulindac—CYP1A1—central nervous system—multiple sclerosis	0.000203	0.00444	CbGeAlD
Sulindac—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000202	0.0958	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000199	0.0943	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000199	0.0943	CbGdCrCtD
Sulindac—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000194	0.0921	CbGdCrCtD
Sulindac—PTGS1—nervous system—multiple sclerosis	0.000185	0.00406	CbGeAlD
Sulindac—PTGS1—central nervous system—multiple sclerosis	0.000178	0.0039	CbGeAlD
Sulindac—PTGS2—nervous system—multiple sclerosis	0.000177	0.00388	CbGeAlD
Sulindac—PTGS2—central nervous system—multiple sclerosis	0.00017	0.00373	CbGeAlD
Sulindac—PTGS2—cerebellum—multiple sclerosis	0.000167	0.00365	CbGeAlD
Sulindac—CYP1A1—brain—multiple sclerosis	0.000161	0.00353	CbGeAlD
Sulindac—PTGS1—brain—multiple sclerosis	0.000141	0.0031	CbGeAlD
Sulindac—PTGS2—brain—multiple sclerosis	0.000135	0.00296	CbGeAlD
Sulindac—Hypertension—Methylprednisolone—multiple sclerosis	9.28e-05	0.00112	CcSEcCtD
Sulindac—Urticaria—Mitoxantrone—multiple sclerosis	9.26e-05	0.00111	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisolone—multiple sclerosis	9.24e-05	0.00111	CcSEcCtD
Sulindac—Body temperature increased—Mitoxantrone—multiple sclerosis	9.21e-05	0.00111	CcSEcCtD
Sulindac—Myalgia—Triamcinolone—multiple sclerosis	9.17e-05	0.0011	CcSEcCtD
Sulindac—Vomiting—Azathioprine—multiple sclerosis	9.17e-05	0.0011	CcSEcCtD
Sulindac—Pneumonia—Methotrexate—multiple sclerosis	9.16e-05	0.0011	CcSEcCtD
Sulindac—Myalgia—Methylprednisolone—multiple sclerosis	9.15e-05	0.0011	CcSEcCtD
Sulindac—Arthralgia—Methylprednisolone—multiple sclerosis	9.15e-05	0.0011	CcSEcCtD
Sulindac—Rash—Azathioprine—multiple sclerosis	9.09e-05	0.00109	CcSEcCtD
Sulindac—Dermatitis—Azathioprine—multiple sclerosis	9.08e-05	0.00109	CcSEcCtD
Sulindac—Depression—Methotrexate—multiple sclerosis	9.08e-05	0.00109	CcSEcCtD
Sulindac—Flushing—Prednisone—multiple sclerosis	9.08e-05	0.00109	CcSEcCtD
Sulindac—Ill-defined disorder—Betamethasone—multiple sclerosis	9.07e-05	0.00109	CcSEcCtD
Sulindac—Ill-defined disorder—Dexamethasone—multiple sclerosis	9.07e-05	0.00109	CcSEcCtD
Sulindac—Discomfort—Triamcinolone—multiple sclerosis	9.06e-05	0.00109	CcSEcCtD
Sulindac—Discomfort—Methylprednisolone—multiple sclerosis	9.04e-05	0.00109	CcSEcCtD
Sulindac—Headache—Azathioprine—multiple sclerosis	9.03e-05	0.00109	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	9.03e-05	0.00109	CcSEcCtD
Sulindac—Renal failure—Methotrexate—multiple sclerosis	8.95e-05	0.00108	CcSEcCtD
Sulindac—Angioedema—Dexamethasone—multiple sclerosis	8.93e-05	0.00107	CcSEcCtD
Sulindac—Angioedema—Betamethasone—multiple sclerosis	8.93e-05	0.00107	CcSEcCtD
Sulindac—Stomatitis—Methotrexate—multiple sclerosis	8.87e-05	0.00107	CcSEcCtD
Sulindac—Conjunctivitis—Methotrexate—multiple sclerosis	8.85e-05	0.00106	CcSEcCtD
Sulindac—Malaise—Dexamethasone—multiple sclerosis	8.82e-05	0.00106	CcSEcCtD
Sulindac—Malaise—Betamethasone—multiple sclerosis	8.82e-05	0.00106	CcSEcCtD
Sulindac—Anaphylactic shock—Triamcinolone—multiple sclerosis	8.79e-05	0.00106	CcSEcCtD
Sulindac—Oedema—Triamcinolone—multiple sclerosis	8.79e-05	0.00106	CcSEcCtD
Sulindac—Vertigo—Dexamethasone—multiple sclerosis	8.78e-05	0.00106	CcSEcCtD
Sulindac—Vertigo—Betamethasone—multiple sclerosis	8.78e-05	0.00106	CcSEcCtD
Sulindac—Anaphylactic shock—Methylprednisolone—multiple sclerosis	8.77e-05	0.00106	CcSEcCtD
Sulindac—Syncope—Betamethasone—multiple sclerosis	8.77e-05	0.00105	CcSEcCtD
Sulindac—Syncope—Dexamethasone—multiple sclerosis	8.77e-05	0.00105	CcSEcCtD
Sulindac—Arrhythmia—Prednisone—multiple sclerosis	8.74e-05	0.00105	CcSEcCtD
Sulindac—Sweating—Methotrexate—multiple sclerosis	8.73e-05	0.00105	CcSEcCtD
Sulindac—Haematuria—Methotrexate—multiple sclerosis	8.68e-05	0.00104	CcSEcCtD
Sulindac—Shock—Triamcinolone—multiple sclerosis	8.65e-05	0.00104	CcSEcCtD
Sulindac—Insomnia—Prednisolone—multiple sclerosis	8.65e-05	0.00104	CcSEcCtD
Sulindac—Alopecia—Prednisone—multiple sclerosis	8.64e-05	0.00104	CcSEcCtD
Sulindac—Shock—Methylprednisolone—multiple sclerosis	8.63e-05	0.00104	CcSEcCtD
Sulindac—Loss of consciousness—Betamethasone—multiple sclerosis	8.59e-05	0.00103	CcSEcCtD
Sulindac—Loss of consciousness—Dexamethasone—multiple sclerosis	8.59e-05	0.00103	CcSEcCtD
Sulindac—Epistaxis—Methotrexate—multiple sclerosis	8.59e-05	0.00103	CcSEcCtD
Sulindac—Hypersensitivity—Mitoxantrone—multiple sclerosis	8.59e-05	0.00103	CcSEcCtD
Sulindac—Paraesthesia—Prednisolone—multiple sclerosis	8.59e-05	0.00103	CcSEcCtD
Sulindac—Tachycardia—Triamcinolone—multiple sclerosis	8.58e-05	0.00103	CcSEcCtD
Sulindac—Nausea—Azathioprine—multiple sclerosis	8.56e-05	0.00103	CcSEcCtD
Sulindac—Tachycardia—Methylprednisolone—multiple sclerosis	8.56e-05	0.00103	CcSEcCtD
Sulindac—Hyperhidrosis—Triamcinolone—multiple sclerosis	8.5e-05	0.00102	CcSEcCtD
Sulindac—Agranulocytosis—Methotrexate—multiple sclerosis	8.5e-05	0.00102	CcSEcCtD
Sulindac—Hyperhidrosis—Methylprednisolone—multiple sclerosis	8.48e-05	0.00102	CcSEcCtD
Sulindac—Convulsion—Betamethasone—multiple sclerosis	8.47e-05	0.00102	CcSEcCtD
Sulindac—Convulsion—Dexamethasone—multiple sclerosis	8.47e-05	0.00102	CcSEcCtD
Sulindac—Hypertension—Betamethasone—multiple sclerosis	8.44e-05	0.00102	CcSEcCtD
Sulindac—Hypertension—Dexamethasone—multiple sclerosis	8.44e-05	0.00102	CcSEcCtD
Sulindac—Asthenia—Mitoxantrone—multiple sclerosis	8.36e-05	0.00101	CcSEcCtD
Sulindac—Myalgia—Dexamethasone—multiple sclerosis	8.32e-05	0.001	CcSEcCtD
Sulindac—Myalgia—Betamethasone—multiple sclerosis	8.32e-05	0.001	CcSEcCtD
Sulindac—Discomfort—Dexamethasone—multiple sclerosis	8.22e-05	0.000989	CcSEcCtD
Sulindac—Discomfort—Betamethasone—multiple sclerosis	8.22e-05	0.000989	CcSEcCtD
Sulindac—Hypotension—Methylprednisolone—multiple sclerosis	8.2e-05	0.000986	CcSEcCtD
Sulindac—Hepatitis—Methotrexate—multiple sclerosis	8.17e-05	0.000983	CcSEcCtD
Sulindac—Vision blurred—Prednisone—multiple sclerosis	8.02e-05	0.000965	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	8.01e-05	0.000964	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	7.99e-05	0.000961	CcSEcCtD
Sulindac—Oedema—Betamethasone—multiple sclerosis	7.98e-05	0.00096	CcSEcCtD
Sulindac—Anaphylactic shock—Dexamethasone—multiple sclerosis	7.98e-05	0.00096	CcSEcCtD
Sulindac—Anaphylactic shock—Betamethasone—multiple sclerosis	7.98e-05	0.00096	CcSEcCtD
Sulindac—Oedema—Dexamethasone—multiple sclerosis	7.98e-05	0.00096	CcSEcCtD
Sulindac—Diarrhoea—Mitoxantrone—multiple sclerosis	7.97e-05	0.000959	CcSEcCtD
Sulindac—Insomnia—Triamcinolone—multiple sclerosis	7.95e-05	0.000957	CcSEcCtD
Sulindac—Insomnia—Methylprednisolone—multiple sclerosis	7.93e-05	0.000954	CcSEcCtD
Sulindac—Ill-defined disorder—Prednisone—multiple sclerosis	7.9e-05	0.00095	CcSEcCtD
Sulindac—Paraesthesia—Triamcinolone—multiple sclerosis	7.9e-05	0.00095	CcSEcCtD
Sulindac—Feeling abnormal—Prednisolone—multiple sclerosis	7.88e-05	0.000948	CcSEcCtD
Sulindac—Paraesthesia—Methylprednisolone—multiple sclerosis	7.88e-05	0.000948	CcSEcCtD
Sulindac—Visual impairment—Methotrexate—multiple sclerosis	7.88e-05	0.000947	CcSEcCtD
Sulindac—Anaemia—Prednisone—multiple sclerosis	7.87e-05	0.000946	CcSEcCtD
Sulindac—Shock—Betamethasone—multiple sclerosis	7.85e-05	0.000944	CcSEcCtD
Sulindac—Shock—Dexamethasone—multiple sclerosis	7.85e-05	0.000944	CcSEcCtD
Sulindac—Dyspnoea—Triamcinolone—multiple sclerosis	7.84e-05	0.000943	CcSEcCtD
Sulindac—Thrombocytopenia—Betamethasone—multiple sclerosis	7.81e-05	0.00094	CcSEcCtD
Sulindac—Thrombocytopenia—Dexamethasone—multiple sclerosis	7.81e-05	0.00094	CcSEcCtD
Sulindac—Tachycardia—Dexamethasone—multiple sclerosis	7.79e-05	0.000937	CcSEcCtD
Sulindac—Tachycardia—Betamethasone—multiple sclerosis	7.79e-05	0.000937	CcSEcCtD
Sulindac—Angioedema—Prednisone—multiple sclerosis	7.78e-05	0.000936	CcSEcCtD
Sulindac—Dyspepsia—Triamcinolone—multiple sclerosis	7.74e-05	0.000931	CcSEcCtD
Sulindac—Erythema multiforme—Methotrexate—multiple sclerosis	7.73e-05	0.000929	CcSEcCtD
Sulindac—Dyspepsia—Methylprednisolone—multiple sclerosis	7.72e-05	0.000929	CcSEcCtD
Sulindac—Hyperhidrosis—Betamethasone—multiple sclerosis	7.71e-05	0.000928	CcSEcCtD
Sulindac—Hyperhidrosis—Dexamethasone—multiple sclerosis	7.71e-05	0.000928	CcSEcCtD
Sulindac—Malaise—Prednisone—multiple sclerosis	7.68e-05	0.000923	CcSEcCtD
Sulindac—Vertigo—Prednisone—multiple sclerosis	7.65e-05	0.00092	CcSEcCtD
Sulindac—Syncope—Prednisone—multiple sclerosis	7.63e-05	0.000918	CcSEcCtD
Sulindac—Tinnitus—Methotrexate—multiple sclerosis	7.62e-05	0.000917	CcSEcCtD
Sulindac—Anorexia—Betamethasone—multiple sclerosis	7.6e-05	0.000915	CcSEcCtD
Sulindac—Anorexia—Dexamethasone—multiple sclerosis	7.6e-05	0.000915	CcSEcCtD
Sulindac—Urticaria—Prednisolone—multiple sclerosis	7.6e-05	0.000914	CcSEcCtD
Sulindac—Fatigue—Triamcinolone—multiple sclerosis	7.58e-05	0.000912	CcSEcCtD
Sulindac—Fatigue—Methylprednisolone—multiple sclerosis	7.56e-05	0.00091	CcSEcCtD
Sulindac—Loss of consciousness—Prednisone—multiple sclerosis	7.48e-05	0.0009	CcSEcCtD
Sulindac—Hypotension—Betamethasone—multiple sclerosis	7.46e-05	0.000897	CcSEcCtD
Sulindac—Hypotension—Dexamethasone—multiple sclerosis	7.46e-05	0.000897	CcSEcCtD
Sulindac—Vomiting—Mitoxantrone—multiple sclerosis	7.41e-05	0.000891	CcSEcCtD
Sulindac—Convulsion—Prednisone—multiple sclerosis	7.38e-05	0.000887	CcSEcCtD
Sulindac—Hypertension—Prednisone—multiple sclerosis	7.35e-05	0.000884	CcSEcCtD
Sulindac—Rash—Mitoxantrone—multiple sclerosis	7.35e-05	0.000884	CcSEcCtD
Sulindac—Dermatitis—Mitoxantrone—multiple sclerosis	7.34e-05	0.000883	CcSEcCtD
Sulindac—Chills—Methotrexate—multiple sclerosis	7.33e-05	0.000882	CcSEcCtD
Sulindac—Headache—Mitoxantrone—multiple sclerosis	7.3e-05	0.000878	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	7.27e-05	0.000874	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	7.27e-05	0.000874	CcSEcCtD
Sulindac—Arthralgia—Prednisone—multiple sclerosis	7.25e-05	0.000872	CcSEcCtD
Sulindac—Myalgia—Prednisone—multiple sclerosis	7.25e-05	0.000872	CcSEcCtD
Sulindac—Feeling abnormal—Triamcinolone—multiple sclerosis	7.25e-05	0.000872	CcSEcCtD
Sulindac—Feeling abnormal—Methylprednisolone—multiple sclerosis	7.23e-05	0.00087	CcSEcCtD
Sulindac—Alopecia—Methotrexate—multiple sclerosis	7.22e-05	0.000869	CcSEcCtD
Sulindac—Insomnia—Dexamethasone—multiple sclerosis	7.22e-05	0.000868	CcSEcCtD
Sulindac—Insomnia—Betamethasone—multiple sclerosis	7.22e-05	0.000868	CcSEcCtD
Sulindac—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	7.17e-05	0.000863	CcSEcCtD
Sulindac—Paraesthesia—Dexamethasone—multiple sclerosis	7.16e-05	0.000862	CcSEcCtD
Sulindac—Paraesthesia—Betamethasone—multiple sclerosis	7.16e-05	0.000862	CcSEcCtD
Sulindac—Discomfort—Prednisone—multiple sclerosis	7.16e-05	0.000861	CcSEcCtD
Sulindac—Hypersensitivity—Prednisolone—multiple sclerosis	7.04e-05	0.000847	CcSEcCtD
Sulindac—Dyspepsia—Dexamethasone—multiple sclerosis	7.02e-05	0.000845	CcSEcCtD
Sulindac—Dyspepsia—Betamethasone—multiple sclerosis	7.02e-05	0.000845	CcSEcCtD
Sulindac—Urticaria—Triamcinolone—multiple sclerosis	6.99e-05	0.00084	CcSEcCtD
Sulindac—Urticaria—Methylprednisolone—multiple sclerosis	6.97e-05	0.000838	CcSEcCtD
Sulindac—Dysgeusia—Methotrexate—multiple sclerosis	6.97e-05	0.000838	CcSEcCtD
Sulindac—Body temperature increased—Triamcinolone—multiple sclerosis	6.95e-05	0.000836	CcSEcCtD
Sulindac—Oedema—Prednisone—multiple sclerosis	6.95e-05	0.000836	CcSEcCtD
Sulindac—Anaphylactic shock—Prednisone—multiple sclerosis	6.95e-05	0.000836	CcSEcCtD
Sulindac—Decreased appetite—Dexamethasone—multiple sclerosis	6.94e-05	0.000834	CcSEcCtD
Sulindac—Decreased appetite—Betamethasone—multiple sclerosis	6.94e-05	0.000834	CcSEcCtD
Sulindac—Nausea—Mitoxantrone—multiple sclerosis	6.92e-05	0.000833	CcSEcCtD
Sulindac—Fatigue—Dexamethasone—multiple sclerosis	6.88e-05	0.000827	CcSEcCtD
Sulindac—Fatigue—Betamethasone—multiple sclerosis	6.88e-05	0.000827	CcSEcCtD
Sulindac—Shock—Prednisone—multiple sclerosis	6.84e-05	0.000822	CcSEcCtD
Sulindac—Tachycardia—Prednisone—multiple sclerosis	6.78e-05	0.000816	CcSEcCtD
Sulindac—Hyperhidrosis—Prednisone—multiple sclerosis	6.72e-05	0.000808	CcSEcCtD
Sulindac—Vision blurred—Methotrexate—multiple sclerosis	6.71e-05	0.000806	CcSEcCtD
Sulindac—Anorexia—Prednisone—multiple sclerosis	6.62e-05	0.000797	CcSEcCtD
Sulindac—Ill-defined disorder—Methotrexate—multiple sclerosis	6.6e-05	0.000794	CcSEcCtD
Sulindac—Anaemia—Methotrexate—multiple sclerosis	6.58e-05	0.000791	CcSEcCtD
Sulindac—Feeling abnormal—Dexamethasone—multiple sclerosis	6.57e-05	0.000791	CcSEcCtD
Sulindac—Feeling abnormal—Betamethasone—multiple sclerosis	6.57e-05	0.000791	CcSEcCtD
Sulindac—Gastrointestinal pain—Betamethasone—multiple sclerosis	6.52e-05	0.000785	CcSEcCtD
Sulindac—Gastrointestinal pain—Dexamethasone—multiple sclerosis	6.52e-05	0.000785	CcSEcCtD
Sulindac—Hypersensitivity—Triamcinolone—multiple sclerosis	6.48e-05	0.000779	CcSEcCtD
Sulindac—Hypersensitivity—Methylprednisolone—multiple sclerosis	6.46e-05	0.000777	CcSEcCtD
Sulindac—Malaise—Methotrexate—multiple sclerosis	6.42e-05	0.000772	CcSEcCtD
Sulindac—Vertigo—Methotrexate—multiple sclerosis	6.39e-05	0.000769	CcSEcCtD
Sulindac—Leukopenia—Methotrexate—multiple sclerosis	6.37e-05	0.000766	CcSEcCtD
Sulindac—Urticaria—Betamethasone—multiple sclerosis	6.34e-05	0.000762	CcSEcCtD
Sulindac—Urticaria—Dexamethasone—multiple sclerosis	6.34e-05	0.000762	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Prednisone—multiple sclerosis	6.33e-05	0.000761	CcSEcCtD
Sulindac—Dizziness—Prednisolone—multiple sclerosis	6.32e-05	0.00076	CcSEcCtD
Sulindac—Asthenia—Triamcinolone—multiple sclerosis	6.31e-05	0.000759	CcSEcCtD
Sulindac—Body temperature increased—Dexamethasone—multiple sclerosis	6.31e-05	0.000759	CcSEcCtD
Sulindac—Body temperature increased—Betamethasone—multiple sclerosis	6.31e-05	0.000759	CcSEcCtD
Sulindac—Asthenia—Methylprednisolone—multiple sclerosis	6.29e-05	0.000757	CcSEcCtD
Sulindac—Insomnia—Prednisone—multiple sclerosis	6.28e-05	0.000756	CcSEcCtD
Sulindac—Paraesthesia—Prednisone—multiple sclerosis	6.24e-05	0.00075	CcSEcCtD
Sulindac—Pruritus—Triamcinolone—multiple sclerosis	6.22e-05	0.000748	CcSEcCtD
Sulindac—Pruritus—Methylprednisolone—multiple sclerosis	6.21e-05	0.000747	CcSEcCtD
Sulindac—Convulsion—Methotrexate—multiple sclerosis	6.16e-05	0.000741	CcSEcCtD
Sulindac—Dyspepsia—Prednisone—multiple sclerosis	6.12e-05	0.000736	CcSEcCtD
Sulindac—Chest pain—Methotrexate—multiple sclerosis	6.06e-05	0.000729	CcSEcCtD
Sulindac—Arthralgia—Methotrexate—multiple sclerosis	6.06e-05	0.000729	CcSEcCtD
Sulindac—Myalgia—Methotrexate—multiple sclerosis	6.06e-05	0.000729	CcSEcCtD
Sulindac—Decreased appetite—Prednisone—multiple sclerosis	6.04e-05	0.000726	CcSEcCtD
Sulindac—Rash—Prednisolone—multiple sclerosis	6.03e-05	0.000725	CcSEcCtD
Sulindac—Dermatitis—Prednisolone—multiple sclerosis	6.02e-05	0.000724	CcSEcCtD
Sulindac—Diarrhoea—Methylprednisolone—multiple sclerosis	6e-05	0.000722	CcSEcCtD
Sulindac—Fatigue—Prednisone—multiple sclerosis	5.99e-05	0.00072	CcSEcCtD
Sulindac—Headache—Prednisolone—multiple sclerosis	5.99e-05	0.00072	CcSEcCtD
Sulindac—Discomfort—Methotrexate—multiple sclerosis	5.98e-05	0.00072	CcSEcCtD
Sulindac—Constipation—Prednisone—multiple sclerosis	5.94e-05	0.000715	CcSEcCtD
Sulindac—Dizziness—Triamcinolone—multiple sclerosis	5.81e-05	0.000699	CcSEcCtD
Sulindac—Anaphylactic shock—Methotrexate—multiple sclerosis	5.81e-05	0.000698	CcSEcCtD
Sulindac—Dizziness—Methylprednisolone—multiple sclerosis	5.8e-05	0.000698	CcSEcCtD
Sulindac—Feeling abnormal—Prednisone—multiple sclerosis	5.73e-05	0.000689	CcSEcCtD
Sulindac—Asthenia—Dexamethasone—multiple sclerosis	5.72e-05	0.000688	CcSEcCtD
Sulindac—Asthenia—Betamethasone—multiple sclerosis	5.72e-05	0.000688	CcSEcCtD
Sulindac—Thrombocytopenia—Methotrexate—multiple sclerosis	5.69e-05	0.000684	CcSEcCtD
Sulindac—Gastrointestinal pain—Prednisone—multiple sclerosis	5.68e-05	0.000683	CcSEcCtD
Sulindac—Nausea—Prednisolone—multiple sclerosis	5.68e-05	0.000683	CcSEcCtD
Sulindac—Pruritus—Betamethasone—multiple sclerosis	5.64e-05	0.000679	CcSEcCtD
Sulindac—Pruritus—Dexamethasone—multiple sclerosis	5.64e-05	0.000679	CcSEcCtD
Sulindac—Hyperhidrosis—Methotrexate—multiple sclerosis	5.61e-05	0.000675	CcSEcCtD
Sulindac—Vomiting—Triamcinolone—multiple sclerosis	5.59e-05	0.000672	CcSEcCtD
Sulindac—Vomiting—Methylprednisolone—multiple sclerosis	5.58e-05	0.000671	CcSEcCtD
Sulindac—Rash—Triamcinolone—multiple sclerosis	5.54e-05	0.000667	CcSEcCtD
Sulindac—Dermatitis—Triamcinolone—multiple sclerosis	5.54e-05	0.000666	CcSEcCtD
Sulindac—Anorexia—Methotrexate—multiple sclerosis	5.53e-05	0.000666	CcSEcCtD
Sulindac—Rash—Methylprednisolone—multiple sclerosis	5.53e-05	0.000665	CcSEcCtD
Sulindac—Dermatitis—Methylprednisolone—multiple sclerosis	5.53e-05	0.000665	CcSEcCtD
Sulindac—Urticaria—Prednisone—multiple sclerosis	5.52e-05	0.000664	CcSEcCtD
Sulindac—Headache—Triamcinolone—multiple sclerosis	5.51e-05	0.000663	CcSEcCtD
Sulindac—Headache—Methylprednisolone—multiple sclerosis	5.5e-05	0.000661	CcSEcCtD
Sulindac—Body temperature increased—Prednisone—multiple sclerosis	5.49e-05	0.000661	CcSEcCtD
Sulindac—Diarrhoea—Dexamethasone—multiple sclerosis	5.46e-05	0.000657	CcSEcCtD
Sulindac—Diarrhoea—Betamethasone—multiple sclerosis	5.46e-05	0.000657	CcSEcCtD
Sulindac—Hypotension—Methotrexate—multiple sclerosis	5.43e-05	0.000653	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	5.29e-05	0.000636	CcSEcCtD
Sulindac—Dizziness—Betamethasone—multiple sclerosis	5.28e-05	0.000635	CcSEcCtD
Sulindac—Dizziness—Dexamethasone—multiple sclerosis	5.28e-05	0.000635	CcSEcCtD
Sulindac—Insomnia—Methotrexate—multiple sclerosis	5.25e-05	0.000632	CcSEcCtD
Sulindac—Nausea—Triamcinolone—multiple sclerosis	5.22e-05	0.000628	CcSEcCtD
Sulindac—Paraesthesia—Methotrexate—multiple sclerosis	5.21e-05	0.000627	CcSEcCtD
Sulindac—Nausea—Methylprednisolone—multiple sclerosis	5.21e-05	0.000627	CcSEcCtD
Sulindac—Dyspnoea—Methotrexate—multiple sclerosis	5.18e-05	0.000623	CcSEcCtD
Sulindac—Somnolence—Methotrexate—multiple sclerosis	5.16e-05	0.000621	CcSEcCtD
Sulindac—Hypersensitivity—Prednisone—multiple sclerosis	5.12e-05	0.000616	CcSEcCtD
Sulindac—Dyspepsia—Methotrexate—multiple sclerosis	5.11e-05	0.000615	CcSEcCtD
Sulindac—Vomiting—Dexamethasone—multiple sclerosis	5.07e-05	0.00061	CcSEcCtD
Sulindac—Vomiting—Betamethasone—multiple sclerosis	5.07e-05	0.00061	CcSEcCtD
Sulindac—Decreased appetite—Methotrexate—multiple sclerosis	5.05e-05	0.000607	CcSEcCtD
Sulindac—Rash—Dexamethasone—multiple sclerosis	5.03e-05	0.000605	CcSEcCtD
Sulindac—Rash—Betamethasone—multiple sclerosis	5.03e-05	0.000605	CcSEcCtD
Sulindac—Dermatitis—Betamethasone—multiple sclerosis	5.03e-05	0.000604	CcSEcCtD
Sulindac—Dermatitis—Dexamethasone—multiple sclerosis	5.03e-05	0.000604	CcSEcCtD
Sulindac—Fatigue—Methotrexate—multiple sclerosis	5.01e-05	0.000602	CcSEcCtD
Sulindac—Headache—Dexamethasone—multiple sclerosis	5e-05	0.000601	CcSEcCtD
Sulindac—Headache—Betamethasone—multiple sclerosis	5e-05	0.000601	CcSEcCtD
Sulindac—Asthenia—Prednisone—multiple sclerosis	4.98e-05	0.0006	CcSEcCtD
Sulindac—Pruritus—Prednisone—multiple sclerosis	4.92e-05	0.000591	CcSEcCtD
Sulindac—Feeling abnormal—Methotrexate—multiple sclerosis	4.78e-05	0.000576	CcSEcCtD
Sulindac—Diarrhoea—Prednisone—multiple sclerosis	4.75e-05	0.000572	CcSEcCtD
Sulindac—Gastrointestinal pain—Methotrexate—multiple sclerosis	4.75e-05	0.000571	CcSEcCtD
Sulindac—Nausea—Betamethasone—multiple sclerosis	4.74e-05	0.00057	CcSEcCtD
Sulindac—Nausea—Dexamethasone—multiple sclerosis	4.74e-05	0.00057	CcSEcCtD
Sulindac—Urticaria—Methotrexate—multiple sclerosis	4.61e-05	0.000555	CcSEcCtD
Sulindac—Dizziness—Prednisone—multiple sclerosis	4.59e-05	0.000553	CcSEcCtD
Sulindac—Body temperature increased—Methotrexate—multiple sclerosis	4.59e-05	0.000552	CcSEcCtD
Sulindac—Vomiting—Prednisone—multiple sclerosis	4.42e-05	0.000531	CcSEcCtD
Sulindac—Rash—Prednisone—multiple sclerosis	4.38e-05	0.000527	CcSEcCtD
Sulindac—Dermatitis—Prednisone—multiple sclerosis	4.38e-05	0.000526	CcSEcCtD
Sulindac—Headache—Prednisone—multiple sclerosis	4.35e-05	0.000524	CcSEcCtD
Sulindac—Hypersensitivity—Methotrexate—multiple sclerosis	4.28e-05	0.000515	CcSEcCtD
Sulindac—Asthenia—Methotrexate—multiple sclerosis	4.17e-05	0.000501	CcSEcCtD
Sulindac—Nausea—Prednisone—multiple sclerosis	4.13e-05	0.000496	CcSEcCtD
Sulindac—Pruritus—Methotrexate—multiple sclerosis	4.11e-05	0.000494	CcSEcCtD
Sulindac—Diarrhoea—Methotrexate—multiple sclerosis	3.97e-05	0.000478	CcSEcCtD
Sulindac—Dizziness—Methotrexate—multiple sclerosis	3.84e-05	0.000462	CcSEcCtD
Sulindac—Vomiting—Methotrexate—multiple sclerosis	3.69e-05	0.000444	CcSEcCtD
Sulindac—Rash—Methotrexate—multiple sclerosis	3.66e-05	0.00044	CcSEcCtD
Sulindac—Dermatitis—Methotrexate—multiple sclerosis	3.66e-05	0.00044	CcSEcCtD
Sulindac—Headache—Methotrexate—multiple sclerosis	3.64e-05	0.000438	CcSEcCtD
Sulindac—Nausea—Methotrexate—multiple sclerosis	3.45e-05	0.000415	CcSEcCtD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—MAPK1—multiple sclerosis	1.63e-05	0.000162	CbGpPWpGaD
Sulindac—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—multiple sclerosis	1.62e-05	0.000161	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—CCL2—multiple sclerosis	1.62e-05	0.000161	CbGpPWpGaD
Sulindac—MAPK3—Downstream signaling of activated FGFR—IL6—multiple sclerosis	1.62e-05	0.000161	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—GPR65—multiple sclerosis	1.6e-05	0.000159	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCR2—multiple sclerosis	1.6e-05	0.000159	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB4—IL6—multiple sclerosis	1.6e-05	0.000158	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—MAPK1—multiple sclerosis	1.59e-05	0.000158	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	1.58e-05	0.000156	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.57e-05	0.000156	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	1.55e-05	0.000153	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	1.54e-05	0.000153	CbGpPWpGaD
Sulindac—MAPK3—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.54e-05	0.000153	CbGpPWpGaD
Sulindac—MAPK3—Downstream signal transduction—IL6—multiple sclerosis	1.53e-05	0.000151	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—PGR—multiple sclerosis	1.52e-05	0.000151	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR—IL6—multiple sclerosis	1.52e-05	0.000151	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	1.51e-05	0.00015	CbGpPWpGaD
Sulindac—MAPK3—Signaling by ERBB2—IL6—multiple sclerosis	1.51e-05	0.00015	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP24A1—multiple sclerosis	1.51e-05	0.000149	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CYP27B1—multiple sclerosis	1.51e-05	0.000149	CbGpPWpGaD
Sulindac—MAPK3—DAP12 signaling—IL6—multiple sclerosis	1.5e-05	0.000149	CbGpPWpGaD
Sulindac—ALB—Folate Metabolism—IL6—multiple sclerosis	1.5e-05	0.000149	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD28—multiple sclerosis	1.49e-05	0.000148	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.48e-05	0.000147	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CNR1—multiple sclerosis	1.48e-05	0.000147	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TYK2—multiple sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Sulindac—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—STAT3—multiple sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCR1—multiple sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL13—multiple sclerosis	1.47e-05	0.000146	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTPRC—multiple sclerosis	1.46e-05	0.000145	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CCR2—multiple sclerosis	1.46e-05	0.000145	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—TLR4—multiple sclerosis	1.44e-05	0.000143	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	1.44e-05	0.000143	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—RRM1—multiple sclerosis	1.44e-05	0.000143	CbGpPWpGaD
Sulindac—MAPK3—Signaling by FGFR in disease—IL6—multiple sclerosis	1.41e-05	0.00014	CbGpPWpGaD
Sulindac—MAPK3—DAP12 interactions—IL6—multiple sclerosis	1.41e-05	0.00014	CbGpPWpGaD
Sulindac—MAPK3—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	1.41e-05	0.00014	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DPB1—multiple sclerosis	1.41e-05	0.00014	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MMP9—multiple sclerosis	1.4e-05	0.000139	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	1.4e-05	0.000139	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR—IL6—multiple sclerosis	1.4e-05	0.000139	CbGpPWpGaD
Sulindac—MAPK3—Signaling by EGFR in Cancer—IL6—multiple sclerosis	1.39e-05	0.000138	CbGpPWpGaD
Sulindac—MAPK3—Signaling by PDGF—IL6—multiple sclerosis	1.38e-05	0.000137	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—STAT3—multiple sclerosis	1.38e-05	0.000137	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GPC5—multiple sclerosis	1.38e-05	0.000137	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD28—multiple sclerosis	1.38e-05	0.000136	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40—multiple sclerosis	1.36e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ITGA4—multiple sclerosis	1.36e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Cellular Senescence—IL6—multiple sclerosis	1.36e-05	0.000135	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNB1—multiple sclerosis	1.35e-05	0.000134	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CTLA4—multiple sclerosis	1.34e-05	0.000133	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—MAPK1—multiple sclerosis	1.34e-05	0.000133	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	1.34e-05	0.000133	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	1.34e-05	0.000133	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CD80—multiple sclerosis	1.33e-05	0.000132	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL10—multiple sclerosis	1.33e-05	0.000132	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.31e-05	0.00013	CbGpPWpGaD
Sulindac—PPARD—Metabolism—APOE—multiple sclerosis	1.3e-05	0.000129	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—ALB—multiple sclerosis	1.28e-05	0.000127	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	1.28e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TYK2—multiple sclerosis	1.27e-05	0.000126	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—MAPK1—multiple sclerosis	1.25e-05	0.000124	CbGpPWpGaD
Sulindac—MAPK3—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	1.25e-05	0.000124	CbGpPWpGaD
Sulindac—ALB—Hemostasis—ITGA4—multiple sclerosis	1.25e-05	0.000124	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IFNB1—multiple sclerosis	1.24e-05	0.000123	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL2—multiple sclerosis	1.23e-05	0.000122	CbGpPWpGaD
Sulindac—MAPK3—M Phase—MAPK1—multiple sclerosis	1.22e-05	0.000121	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GPC5—multiple sclerosis	1.22e-05	0.000121	CbGpPWpGaD
Sulindac—PTGDR2—Signaling by GPCR—IL6—multiple sclerosis	1.22e-05	0.000121	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP24A1—multiple sclerosis	1.22e-05	0.000121	CbGpPWpGaD
Sulindac—ALB—Metabolism—CYP27B1—multiple sclerosis	1.22e-05	0.000121	CbGpPWpGaD
Sulindac—MAPK3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	1.21e-05	0.00012	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SRM—multiple sclerosis	1.21e-05	0.00012	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.19e-05	0.000118	CbGpPWpGaD
Sulindac—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	1.19e-05	0.000118	CbGpPWpGaD
Sulindac—MAPK3—Immune System—VCAM1—multiple sclerosis	1.18e-05	0.000117	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DQA1—multiple sclerosis	1.18e-05	0.000117	CbGpPWpGaD
Sulindac—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	1.16e-05	0.000115	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MMP9—multiple sclerosis	1.16e-05	0.000115	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL5—multiple sclerosis	1.14e-05	0.000114	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—RRM1—multiple sclerosis	1.14e-05	0.000113	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—MAPK1—multiple sclerosis	1.13e-05	0.000113	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—TYK2—multiple sclerosis	1.12e-05	0.000111	CbGpPWpGaD
Sulindac—MAPK3—Mitotic M-M/G1 phases—MAPK1—multiple sclerosis	1.12e-05	0.000111	CbGpPWpGaD
Sulindac—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.12e-05	0.000111	CbGpPWpGaD
Sulindac—PPARD—Metabolism—POMC—multiple sclerosis	1.12e-05	0.000111	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.12e-05	0.000111	CbGpPWpGaD
Sulindac—ALB—Metabolism—GPC5—multiple sclerosis	1.11e-05	0.00011	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DQB1—multiple sclerosis	1.1e-05	0.000109	CbGpPWpGaD
Sulindac—PTGS2—Disease—RPL5—multiple sclerosis	1.07e-05	0.000106	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—VDR—multiple sclerosis	1.07e-05	0.000106	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD86—multiple sclerosis	1.06e-05	0.000105	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	1.05e-05	0.000104	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	1.05e-05	0.000104	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL3—multiple sclerosis	1.05e-05	0.000104	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD40LG—multiple sclerosis	1.04e-05	0.000103	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—IL2—multiple sclerosis	1.04e-05	0.000103	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—STAT3—multiple sclerosis	1.03e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCR5—multiple sclerosis	1.03e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD8A—multiple sclerosis	1.03e-05	0.000102	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	1.03e-05	0.000102	CbGpPWpGaD
Sulindac—MAPK3—Cellular responses to stress—IL6—multiple sclerosis	1.03e-05	0.000102	CbGpPWpGaD
Sulindac—SLC22A6—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.03e-05	0.000102	CbGpPWpGaD
Sulindac—PTGS2—Disease—SLC11A1—multiple sclerosis	1.02e-05	0.000102	CbGpPWpGaD
Sulindac—PPARD—Metabolism—ALB—multiple sclerosis	1.02e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2RA—multiple sclerosis	1.02e-05	0.000101	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—CD4—multiple sclerosis	1.02e-05	0.000101	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—RRM1—multiple sclerosis	1.01e-05	0.0001	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTGER4—multiple sclerosis	1.01e-05	9.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MMP9—multiple sclerosis	1e-05	9.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-B—multiple sclerosis	9.91e-06	9.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PGR—multiple sclerosis	9.91e-06	9.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD86—multiple sclerosis	9.81e-06	9.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	9.81e-06	9.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Cytokine Signaling in Immune system—IL6—multiple sclerosis	9.8e-06	9.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCR3—multiple sclerosis	9.72e-06	9.64e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	9.69e-06	9.61e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by NGF—IL6—multiple sclerosis	9.64e-06	9.55e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CD28—multiple sclerosis	9.63e-06	9.55e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MYC—multiple sclerosis	9.59e-06	9.51e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.58e-06	9.5e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—TGFB1—multiple sclerosis	9.57e-06	9.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCR2—multiple sclerosis	9.46e-06	9.38e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—MAPK1—multiple sclerosis	9.39e-06	9.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2RA—multiple sclerosis	9.29e-06	9.21e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—RRM1—multiple sclerosis	9.23e-06	9.16e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-A—multiple sclerosis	9.18e-06	9.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—STAT3—multiple sclerosis	8.91e-06	8.83e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	8.85e-06	8.78e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.73e-06	8.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CNR1—multiple sclerosis	8.73e-06	8.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Axon guidance—IL6—multiple sclerosis	8.72e-06	8.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CCR5—multiple sclerosis	8.7e-06	8.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MYC—multiple sclerosis	8.57e-06	8.5e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2RA—multiple sclerosis	8.52e-06	8.45e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	8.52e-06	8.45e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	8.52e-06	8.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—HLA-A—multiple sclerosis	8.48e-06	8.41e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TLR4—multiple sclerosis	8.4e-06	8.33e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—HLA-DRB1—multiple sclerosis	8.39e-06	8.32e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	8.38e-06	8.31e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	8.33e-06	8.26e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—MYC—multiple sclerosis	8.29e-06	8.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TGFB1—multiple sclerosis	8.26e-06	8.19e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—BCHE—multiple sclerosis	8.26e-06	8.19e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD28—multiple sclerosis	8.18e-06	8.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TGFB1—multiple sclerosis	8.1e-06	8.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—MAPK1—multiple sclerosis	8.1e-06	8.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—POMC—multiple sclerosis	8.06e-06	7.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ICAM1—multiple sclerosis	8.05e-06	7.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—MAPK1—multiple sclerosis	7.94e-06	7.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—APOE—multiple sclerosis	7.92e-06	7.85e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CCL2—multiple sclerosis	7.89e-06	7.82e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL10—multiple sclerosis	7.86e-06	7.79e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.86e-06	7.79e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GPC5—multiple sclerosis	7.79e-06	7.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD80—multiple sclerosis	7.75e-06	7.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—TNF—multiple sclerosis	7.71e-06	7.65e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MYC—multiple sclerosis	7.66e-06	7.6e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	7.61e-06	7.54e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	7.56e-06	7.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—MAPK1—multiple sclerosis	7.5e-06	7.43e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	7.42e-06	7.35e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—IL6—multiple sclerosis	7.21e-06	7.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—TYK2—multiple sclerosis	7.16e-06	7.1e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.16e-06	7.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD80—multiple sclerosis	7.16e-06	7.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—MAPK1—multiple sclerosis	7.15e-06	7.09e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.93e-06	6.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CD86—multiple sclerosis	6.87e-06	6.81e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL5—multiple sclerosis	6.76e-06	6.71e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.75e-06	6.69e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—BCHE—multiple sclerosis	6.55e-06	6.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—TYK2—multiple sclerosis	6.54e-06	6.49e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—RRM1—multiple sclerosis	6.46e-06	6.4e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SPP1—multiple sclerosis	6.26e-06	6.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—IL6—multiple sclerosis	6.22e-06	6.17e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	6.15e-06	6.1e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.15e-06	6.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNG—multiple sclerosis	6.13e-06	6.08e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCR5—multiple sclerosis	6.09e-06	6.04e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TYK2—multiple sclerosis	6.04e-06	5.99e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2RA—multiple sclerosis	6.01e-06	5.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—multiple sclerosis	5.96e-06	5.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—CD4—multiple sclerosis	5.92e-06	5.87e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD86—multiple sclerosis	5.83e-06	5.79e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—BCHE—multiple sclerosis	5.82e-06	5.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APOE—multiple sclerosis	5.54e-06	5.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—IL6—multiple sclerosis	5.5e-06	5.45e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1B—multiple sclerosis	5.47e-06	5.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—CD4—multiple sclerosis	5.46e-06	5.42e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—multiple sclerosis	5.45e-06	5.4e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—BCHE—multiple sclerosis	5.3e-06	5.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CCR5—multiple sclerosis	5.17e-06	5.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HLA-A—multiple sclerosis	5.04e-06	5e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CD80—multiple sclerosis	5.01e-06	4.97e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.01e-06	4.97e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—multiple sclerosis	5e-06	4.96e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—APOE—multiple sclerosis	4.97e-06	4.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—POMC—multiple sclerosis	4.76e-06	4.72e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APOE—multiple sclerosis	4.71e-06	4.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CCL2—multiple sclerosis	4.66e-06	4.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—multiple sclerosis	4.58e-06	4.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—MAPK1—multiple sclerosis	4.56e-06	4.52e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.3e-06	4.27e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—POMC—multiple sclerosis	4.27e-06	4.23e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD80—multiple sclerosis	4.26e-06	4.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—multiple sclerosis	4.23e-06	4.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TYK2—multiple sclerosis	4.23e-06	4.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—multiple sclerosis	4.23e-06	4.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MAPK1—multiple sclerosis	4.17e-06	4.13e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—APOE—multiple sclerosis	3.94e-06	3.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—multiple sclerosis	3.93e-06	3.9e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.92e-06	3.89e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—TGFB1—multiple sclerosis	3.92e-06	3.89e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TGFB1—multiple sclerosis	3.9e-06	3.87e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—ALB—multiple sclerosis	3.89e-06	3.86e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MAPK1—multiple sclerosis	3.85e-06	3.81e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—MAPK1—multiple sclerosis	3.82e-06	3.79e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BCHE—multiple sclerosis	3.71e-06	3.68e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TYK2—multiple sclerosis	3.59e-06	3.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—multiple sclerosis	3.52e-06	3.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL6—multiple sclerosis	3.5e-06	3.47e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—APOE—multiple sclerosis	3.5e-06	3.47e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—POMC—multiple sclerosis	3.39e-06	3.36e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—multiple sclerosis	3.33e-06	3.3e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD4—multiple sclerosis	3.25e-06	3.22e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL6—multiple sclerosis	3.2e-06	3.17e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—APOE—multiple sclerosis	3.19e-06	3.16e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—ALB—multiple sclerosis	3.09e-06	3.06e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—POMC—multiple sclerosis	3.01e-06	2.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—multiple sclerosis	2.96e-06	2.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—IL6—multiple sclerosis	2.96e-06	2.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—multiple sclerosis	2.75e-06	2.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TGFB1—multiple sclerosis	2.75e-06	2.72e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—ALB—multiple sclerosis	2.74e-06	2.72e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—POMC—multiple sclerosis	2.74e-06	2.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MAPK1—multiple sclerosis	2.69e-06	2.67e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—multiple sclerosis	2.52e-06	2.5e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—multiple sclerosis	2.34e-06	2.32e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TGFB1—multiple sclerosis	2.33e-06	2.31e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MAPK1—multiple sclerosis	2.29e-06	2.27e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—APOE—multiple sclerosis	2.23e-06	2.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL6—multiple sclerosis	2.07e-06	2.05e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—POMC—multiple sclerosis	1.92e-06	1.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—IL6—multiple sclerosis	1.76e-06	1.74e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—ALB—multiple sclerosis	1.75e-06	1.73e-05	CbGpPWpGaD
